639087-64-2
Chemical Structure
CP-654577
- CAS No.: 639087-64-2
- Formula:C34H32N4O3
- Molecular Weight:544.66
IUPAC Name: ((1R,5S,6r)-3-(4-(4-((3-methoxy-4-phenoxyphenyl)amino)quinazolin-6-yl)benzyl)-3-azabicyclo[3.1.0]hexan-6-yl)methanol
InChIKey: WZZXMNBOPNKKSX-BKHFGAQXSA-N
SMILES: C(O)[C@H]1[C@]2([C@@]1(CN(CC3=CC=C(C=C3)C4=CC=5C(NC6=CC(OC)=C(OC7=CC=CC=C7)C=C6)=NC=NC5C=C4)C2)[H])[H]
Biological Activity: CP-654577 is a selective ErbB2 inhibitor with an IC50 of 11 nM. CP-654577 downregulates the Notch1 signaling pathway. CP-654577 upregulates p27kip1, reduces the levels of Cyclins D and E, and inhibits G1 phase progression of the cell cycle. CP-654577 induces cell Apoptosis, downregulates activated Akt, and suppresses tumor growth in athymic mice. CP-654577 can be used in breast cancer-related research[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
CP-654577 | CP-654577 is a selective ErbB2 inhibitor with an IC50 of 11 nM. CP-654577 downregulates the Notch1 signaling pathway. CP-654577 upregulates p27kip1, reduces the levels of Cyclins D and E, and inhibits G1 phase progression of the cell cycle. CP-654577 induces cell Apoptosis, downregulates activated Akt, and suppresses tumor growth in athymic mice. CP-654577 can be used in breast cancer-related research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Lindsay J, et al. ErbB2 induces Notch1 activity and function in breast cancer cells. Clinical and translational science. 2008 Sep;1(2):107-15. [Content Brief]
- [2]. Barbacci EG, et al. The biological and biochemical effects of CP-654577, a selective erbB2 kinase inhibitor, on human breast cancer cells. Cancer research. 2003 Aug 01;63(15):4450-9. [Content Brief]
- [3]. Rabindran SK, et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer research. 2004 Jun 01;64(11):3958-65. [Content Brief]
